{
    "symbol": "BLRX",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-16 13:00:17",
    "content": " So regardless of the manner in which we commercialize Motixafortide in the U.S., our efforts now will ensure that we are prepared for a robust launch next year that maximizes the value of the asset and ensures that Motixafortide is well positioned to capture a significant share of the estimated $360 million annual market opportunity in the U.S. First, submission of an NDA to the FDA for Motixafortide as a novel mobilization agent for multiple myeloma patients undergoing autologous stem cell transplantation expected in the next 4 to 6 weeks."
}